These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 26857267)

  • 1. Regorafenib Also Can Cause Osteonecrosis of the Jaw.
    Antonuzzo L; Lunghi A; Giommoni E; Brugia M; Di Costanzo F
    J Natl Cancer Inst; 2016 Apr; 108(4):. PubMed ID: 26857267
    [No Abstract]   [Full Text] [Related]  

  • 2. Regorafenib: start low and go slow.
    Tabchi S; Ghosn M
    Target Oncol; 2015 Sep; 10(3):445-7. PubMed ID: 25548130
    [No Abstract]   [Full Text] [Related]  

  • 3. Regorafenib in metastatic colorectal cancer: optimal dosing and patient selection recommendations.
    Grothey A
    Clin Adv Hematol Oncol; 2015 Aug; 13(8):514-7. PubMed ID: 26351814
    [No Abstract]   [Full Text] [Related]  

  • 4. Metastatic colorectal cancer.
    Prescrire Int; 2017 Feb; 26(179):51. PubMed ID: 30726636
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical and molecular assessment of regorafenib monotherapy.
    Kakizawa N; Suzuki K; Fukui T; Takayama Y; Ichida K; Muto Y; Hasegawa F; Watanabe F; Kikugawa R; Tsujinaka S; Futsuhara K; Miyakura Y; Noda H; Rikiyama T
    Oncol Rep; 2017 Apr; 37(4):2506-2512. PubMed ID: 28259999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comment on: "Regorafenib: Start Low and Go Slow".
    de la Fouchardière C
    Target Oncol; 2016 Feb; 11(1):123-5. PubMed ID: 26634250
    [No Abstract]   [Full Text] [Related]  

  • 7. Regorafenib in the treatment of metastatic colorectal cancer.
    de la Fouchardière C
    Future Oncol; 2018 Sep; 14(22):2239-2246. PubMed ID: 29569472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced dose of salvage-line regorafenib monotherapy for metastatic colorectal cancer in Japan.
    Hirano G; Makiyama A; Makiyama C; Esaki T; Oda H; Uchino K; Komoda M; Tanaka R; Matsushita Y; Mitsugi K; Shibata Y; Kumagai H; Arita S; Ariyama H; Kusaba H; Akashi K; Baba E
    Anticancer Res; 2015 Jan; 35(1):371-7. PubMed ID: 25550574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regorafenib in metastatic colorectal cancer.
    Grothey A
    Clin Adv Hematol Oncol; 2012 May; 10(5):324-5. PubMed ID: 22706543
    [No Abstract]   [Full Text] [Related]  

  • 10. Author's Reply to Christelle de la Fouchardière: "Regorafenib: Start Low and Go Slow".
    Tabchi S; Ghosn M
    Target Oncol; 2016 Feb; 11(1):127-8. PubMed ID: 26645827
    [No Abstract]   [Full Text] [Related]  

  • 11. Regorafenib-Associated Vulvar Psoriasiform Skin Reaction: Case of the Month from the ISSVD Case Consultation Committee.
    Bourne EL; Day T; Scurry J
    J Low Genit Tract Dis; 2016 Jul; 20(3):e44-5. PubMed ID: 27195780
    [No Abstract]   [Full Text] [Related]  

  • 12. Adherence and safety of regorafenib for patients with metastatic colorectal cancer: observational real-life study.
    Del Prete S; Cennamo G; Leo L; Montella L; Vincenzi B; Biglietto M; Andreozzi F; Prudente A; Iodice P; Savastano C; Nappi A; Montesarchio V; Addeo R
    Future Oncol; 2017 Feb; 13(5):415-423. PubMed ID: 27780365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regorafenib for Metastatic Colorectal Cancer: Common Toxicities and Prevention Strategies.
    Draper A
    Oncology (Williston Park); 2019 Apr; 33(4):126-7. PubMed ID: 30990563
    [No Abstract]   [Full Text] [Related]  

  • 14. Prophylactic Use of Oral Dexamethasone to Alleviate Fatigue During Regorafenib Treatment for Patients With Metastatic Colorectal Cancer.
    Fukuoka S; Shitara K; Noguchi M; Kawazoe A; Kuboki Y; Bando H; Okamoto W; Kojima T; Doi T; Ohtsu A; Yoshino T
    Clin Colorectal Cancer; 2017 Jun; 16(2):e39-e44. PubMed ID: 27780748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improving patient outcomes with regorafenib for metastatic colorectal cancer - patient selection, dosing, patient education, prophylaxis, and management of adverse events.
    Hofheinz RD; Arnold D; Kubicka S; Prasnikar N; Vogel A
    Oncol Res Treat; 2015; 38(6):300-8. PubMed ID: 26045027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversible posterior leukoencephalopathy syndrome during regorafenib treatment: a case report and literature review of reversible posterior leukoencephalopathy syndrome associated with multikinase inhibitors.
    Myint ZW; Sen JM; Watts NL; Druzgal TJ; Nathan BR; Ward MD; Boyer JE; Fracasso PM
    Clin Colorectal Cancer; 2014 Jun; 13(2):127-30. PubMed ID: 24461491
    [No Abstract]   [Full Text] [Related]  

  • 17. Off-target effects and clinical outcome in metastatic colorectal cancer patients receiving regorafenib: The TRIBUTE analysis.
    Giampieri R; Prete MD; Prochilo T; Puzzoni M; Pusceddu V; Pani F; Maccaroni E; Mascia R; Baleani MG; Meletani T; Berardi R; Lanzillo AM; Mariotti S; Zaniboni A; Cascinu S; Scartozzi M
    Sci Rep; 2017 Apr; 7():45703. PubMed ID: 28378839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Regorafenib in patients with metastatic colorectal cancer: a review and an update].
    Zaniboni A; Mansueto G
    Recenti Prog Med; 2015 Dec; 106(12):629-33. PubMed ID: 26780072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Successful Administration of Regorafenib to a Metastatic Colon Cancer Patient with Impaired Performance Status by Reducing the Initial Dose].
    Nishitai R; Manaka D; Kudo R; Mitsuoka E; Kanai S; Kanto S; Yoshino K; Hamasu SY; Konishi S; Yamashiro Y
    Gan To Kagaku Ryoho; 2015 Jul; 42(7):871-3. PubMed ID: 26197753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Severe Maculopapular Exanthema Induced by Regorafenib: Successful Desensitization and Adaptation of a Dosage Regimen.
    García-Gutiérrez I; Acevedo M; Tornero P; Matilla A; Márquez L; Sánchez-Herrero A; Prieto-García A
    J Investig Allergol Clin Immunol; 2019 Aug; 29(4):300-302. PubMed ID: 31478526
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.